Dr. Cameron Durrant Named One of PharmaVOICE’s 100 Most Inspiring People in the Pharmaceutical Industry for 2010

Recognized for leadership, innovation in annual ranking of top 100 industry professionals Califon, NJ — August 30, 2010 — Anavex Life Sciences Corp., (“Anavex” or the “Company”) (OTCBB: AVXL) is pleased to announce that Dr. Cameron Durrant, the company’s Executive Chairman, has been named in this year’s “PharmaVOICE 100” as one of the 100 most…

Anavex Appoints Contract Research Organizations to Initiate Phase I/IIa Clinical Programs, Regulatory Strategies in Alzheimer’s Disease

Califon, NJ/Basel, Switzerland/Dresden, Germany – August 10, 2010 — Anavex Life Sciences Corp. (“ANAVEX”) (OTCBB: AVXL) today announced that it has signed a definitive master services agreement with Genesis BioPharma Group (“Genesis”) and ABX-CRO Advanced Pharmaceutical Services (“ABX-CRO”) to begin clinical studies and regulatory filings  for ANAVEX 2-73, its lead compound for the treatment of…

Anavex Reports Animal Study Results as Lead Alzheimer’s Compound Approaches Phase 1 Clinical Trials

Geneva, Switzerland — May 4, 2010 — Anavex Life Sciences Corp. (“ANAVEX”) (OTCBB: AVXL) is pleased to report promising results from animal studies with ANAVEX 2-73, the company’s lead compound for the treatment and modification of Alzheimer’s disease.ANAVEX 2-73 is the first of a new class of drugs that target mitochondrial dysfunction thought to be…

Anavex Comments on Failure of Pfizer and Medivation’s Dimebon

Geneva, Switzerland — March 3, 2010 — Anavex Life Sciences Corp. (“ANAVEX”) (OTCBB: AVXL) today issued a statement following today’s announcement from Pfizer and Medivation (NASDAQ:MDVN) that their investigational Alzheimer’s drug Dimebon did not meet either its co-primary or secondary endpoints compared to placebo during pivotal Phase 3 clinical trials. “While this is disappointing for…

Anavex Contracts FORENAP Pharma for Pre-Clinical Trials of ANAVEX 2-73 in Alzheimer’s Disease.

Geneva, Switzerland — September 30, 2009 — Anavex Life Sciences Corp. (“ANAVEX” or the “Company”) (OTCBB: AVXL) has selected FORENAP Pharma EURL (“FORENAP”) as the contract research organization (CRO) for Phase I clinical trials of ANAVEX 2-73, the company’s lead Alzheimer’s drug candidate.  FORENAP has been involved in pre-clinical and clinical research for 20 years…

Anavex Completes Scale-Up Manufacturing of ANAVEX 2-73 for Phase I Alzheimer’s Disease Clinical Trials

Geneva, Switzerland — September 21, 2009 — Anavex Life Sciences Corp., (“ANAVEX”) (OTCBB: AVXL) today announced the completion of scale-up manufacturing of ANAVEX 2-73, its lead compound for the treatment of Alzheimer’s disease.“With sufficient quantities of ANAVEX 2-73 in hand we are an important step closer to the commencement of Phase 1 clinical trials, which…

Anavex Reports Sigma Receptor Review Published in Leading Journal

Geneva, Switzerland — August 27, 2009 — Anavex Life Sciences Corp. (“ANAVEX” or the “Company”) (OTCBB: AVXL) reports the publication of a comprehensive review of the pharmacology of sigma receptors and their possible clinical application in the peer-reviewed Journal of Pharmacology & Therapeutics. The paper provides new insight into sigma-1 receptors and their potential ability…

ANAVEX Appoints Dr. Hervé de Kegrohen as CEO to Lead Company Through Clinical Trials and Future Growth

Geneva, Switzerland — June 16, 2009 — Anavex Life Sciences Corp., (“ANAVEX”) (OTCBB: AVXL) today announced the immediate appointment of Hervé de Kergrohen, MD, MBA, as its Chief Executive Officer (CEO) and director. Dr. de Kergrohen is an accomplished senior executive who has successfully founded and developed numerous life sciences companies throughout his career. With…